BT44|cas:924759-42-2|西域试剂

BT44,99.08%

产品编号：Bellancom-153175| CAS NO：924759-42-2| 分子式：C₂₈H₂₇F₄N₃O₄S| 分子量：577.59

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-153175	￥2300.00	杭州北京（现货）
Bellancom-153175	￥3750.00	杭州北京（现货）
Bellancom-153175	￥7500.00	杭州北京（现货）
Bellancom-153175	￥12000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

BT44

产品介绍

BT44 是选择性 RET 活化剂。BT44 可穿透血脑屏障，可用于研究神经退行性疾病及糖尿病。

生物活性

BT44 is a selective RET activator. BT44 can penetrate through the blood-brain barrier and can be used for the research of neurodegenerative disorders and diabetes mellitus.

体外研究

BT44 (7.5-75 μM; 15 min) 促进 RET 磷酸化并选择性激活表达 GFL 受体的细胞的下游级联反应。
BT44 (0.5-10 μM; 16-20 h) 促进感觉神经元的神经突生长。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	GFRα3-transfected MG87RET cells
Concentration:	7.5, 18, 35 and 75 μM
Incubation Time:	15 min
Result:	Increased RET and ERK phosphorylation.

体内研究
(In Vivo)

BT44 (5-25 mg/kg; s.c.; every second day for 10, 42 or 14 days) 在神经性的 SNL 和 STZ 模型中可减轻感觉体征。
BT44 (12.5 or 25 mg/kg; s.c.; every second day for 10 days) 对实验性神经病变动物 DRGs 中 IB4 阳性神经元有保护作用。
BT44 (0.1 and 0.3 μg/24 h; infuse into the right dorsal striatum for 14 days) 在 6-OHDA 帕金森大鼠模型中逆转 amphetamine 引起的运动失衡，似乎保护纹状体中的多巴胺能纤维。
BT44 (10 mg/kg; i.v.) 穿过血脑屏障，在大鼠中迅速从循环 (半衰期 (t_1/2) = 0.72 h) 和脑 (t_1/2 = 0.47 h) 中消除。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wistar rats, spinal nerve ligation (SNL) and Streptozotocin (STZ; HY-13753)-induced diabetes mellitus models
Dosage:	5, 12.5 or 25 mg/kg
Administration:	Subcutaneous injecton, every second day for 10, 42 or 14 days
Result:	Alleviated mechanical allodynia in the SNL animals. Treatment with the dose of 5 mg/kg alleviated mechanical hyperalgesia in the STZ-treated animals, while the 12.5 mg/kg dose was not effective. Concentration of 5 mg/kg attenuated cold allodynia in the STZ-treated animals during the first two weeks while the effect of 12.5 mg/kg was not significant.

Animal Model:	Wistar rats, SNL-induced diabetes mellitus model
Dosage:	12.5 or 25 mg/kg
Administration:	Subcutaneous injecton, every second day for 10 days
Result:	Led to a significant increase in the number of IB4 expressing neurons in the ipsilateral DRGs. The 12.5 mg/kg dose protected IB4-positive neurons from SNL-induced lesion.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wistar rats, spinal nerve ligation (SNL) and Streptozotocin (STZ; HY-13753)-induced diabetes mellitus models
Dosage:	5, 12.5 or 25 mg/kg
Administration:	Subcutaneous injecton, every second day for 10, 42 or 14 days
Result:	Alleviated mechanical allodynia in the SNL animals. Treatment with the dose of 5 mg/kg alleviated mechanical hyperalgesia in the STZ-treated animals, while the 12.5 mg/kg dose was not effective. Concentration of 5 mg/kg attenuated cold allodynia in the STZ-treated animals during the first two weeks while the effect of 12.5 mg/kg was not significant.

Animal Model:	Wistar rats, SNL-induced diabetes mellitus model
Dosage:	12.5 or 25 mg/kg
Administration:	Subcutaneous injecton, every second day for 10 days
Result:	Led to a significant increase in the number of IB4 expressing neurons in the ipsilateral DRGs. The 12.5 mg/kg dose protected IB4-positive neurons from SNL-induced lesion.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wistar rats, spinal nerve ligation (SNL) and Streptozotocin (STZ; HY-13753)-induced diabetes mellitus models
Dosage:	5, 12.5 or 25 mg/kg
Administration:	Subcutaneous injecton, every second day for 10, 42 or 14 days
Result:	Alleviated mechanical allodynia in the SNL animals. Treatment with the dose of 5 mg/kg alleviated mechanical hyperalgesia in the STZ-treated animals, while the 12.5 mg/kg dose was not effective. Concentration of 5 mg/kg attenuated cold allodynia in the STZ-treated animals during the first two weeks while the effect of 12.5 mg/kg was not significant.

Animal Model:	Wistar rats, SNL-induced diabetes mellitus model
Dosage:	12.5 or 25 mg/kg
Administration:	Subcutaneous injecton, every second day for 10 days
Result:	Led to a significant increase in the number of IB4 expressing neurons in the ipsilateral DRGs. The 12.5 mg/kg dose protected IB4-positive neurons from SNL-induced lesion.

性状

Solid

溶解性数据

In Vitro:

DMSO : 62.5 mg/mL (108.21 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.7313 mL	8.6567 mL	17.3133 mL
5 mM	0.3463 mL	1.7313 mL	3.4627 mL
10 mM	0.1731 mL	0.8657 mL	1.7313 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式